NHS-Galleri试验对癌症诊断延迟的潜在溢出效应
This quasi-experimental study found that NHS-Galleri trial regions experienced higher cancer diagnostic delays for high-detection cancer types, raising concerns about spillover that could overestimate the benefit of MCED testing
来源文章
RAND Corporation (United States) | 2026年4月20日
您的投票很重要
无需账号。您的投票会被保存并计入共识分析。 创建账号即可保存您的投票记录。
AI 翻译 · 显示原文
While MCED testing shows promise, the spillover effects on diagnostic delays must be thoroughly evaluated before widespread adoption.
AI 翻译 · 显示原文
The potential overestimation of MCED benefits due to diagnostic delays calls for a re-examination of how we assess cancer screening effectiveness.
AI 翻译 · 显示原文
Investing in MCED testing could lead to long-term benefits for cancer detection, even if initial trials reveal some diagnostic delays.
AI 翻译 · 显示原文
Higher diagnostic delays in NHS-Galleri trial regions raise serious concerns about the effectiveness of MCED testing and its implementation.
AI 翻译 · 显示原文
The NHS-Galleri trial highlights the importance of early detection, suggesting that MCED testing could save lives despite potential diagnostic delays.
💡 使用说明
- • 添加陈述: 发布观点或问题(10 至 500 个字符)。
- • 投票: 对每条陈述选择同意、不同意或不确定。
- • 回应: 附上证据,详细阐述支持或反对的理由。
- • 共识: 参与人数足够后,分析会显示各意见群体及其共识所在。
Society Speaks 开放且独立。 您的支持让公民讨论远离广告和商业影响。
支持我们